{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:24Z","timestamp":1791521424470,"version":"4.3.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"\n Background<\/jats:title>\n The platelet-to-hemoglobin ratio (PHR) is a proposed prognostic marker in cardiovascular disease, but it has not been evaluated against a broad major adverse cardiovascular events (MACE) endpoint in a dedicated percutaneous coronary intervention (PCI) cohort, and whether it adequately summarizes its two components remains untested.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We analyzed 1,551 patients pooled from two prospective Korean drug-eluting stent registries (2016\u20132022). The PHR was calculated as platelet count (\u00d710\u2079\/L) divided by hemoglobin (g\/L). The primary endpoint was 1-year MACE, with follow-up censored at 365 days, a composite of all-cause death, myocardial infarction, stroke, repeat revascularization, or heart failure hospitalization. Multivariable Cox models included eight prespecified clinical covariates; the functional form was examined with restricted cubic splines, and the PHR was decomposed using nested models and a log-scale ratio-constraint test.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n MACE occurred in 107 patients (6.9%) within 1 year. A higher PHR was independently associated with MACE (adjusted hazard ratio [HR] per 1-standard deviation, 1.21; 95% confidence interval [CI], 1.05\u20131.40;\n P<\/jats:italic>\n \u2009=\u20090.008), with no evidence of nonlinearity (\n P<\/jats:italic>\n \u2009=\u20090.700). Adding the PHR improved the clinical model (likelihood-ratio\n P<\/jats:italic>\n \u2009=\u20090.013); the ratio constraint was not rejected (\n P<\/jats:italic>\n \u2009=\u20090.765), and a single log-PHR term retained 98.7% of the two-component likelihood-ratio\n \u03c7<\/jats:italic>\n 2<\/jats:sup>\n increment over the clinical model in this cohort (bootstrap 95% CI, 21.8%\u2013100%). The PHR was associated with all-cause and cardiovascular death (both HR, 1.28), paralleling hemoglobin. Repeat revascularization was associated with platelet count (HR, 1.39;\n P<\/jats:italic>\n \u2009=\u20090.014), but not significantly with PHR (HR, 1.24;\n P<\/jats:italic>\n \u2009=\u20090.081). Risk was concentrated in patients with both anemia and a platelet count at or above the median (adjusted HR, 1.82; 95% CI, 1.05\u20133.15). The gain in discrimination was negligible (\n \u0394<\/jats:italic>\n AUC, +0.003; 95% CI, \u22120.003 to +0.012), and net benefit was virtually unchanged.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The admission PHR was independently associated with 1-year MACE after PCI, with no evidence of nonlinearity, and its log-scale component effects were compatible with the ratio constraint in this cohort. Given the negligible gain in discrimination and net benefit, the PHR is an independent prognostic marker rather than a tool for risk reclassification.<\/jats:p>\n \n Registry registration:<\/jats:bold>\n Clinical Research Information Service KCT0003392 and KCT0005008.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1981126","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:26Z","timestamp":1791519986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Admission platelet-to-hemoglobin ratio and 1-year outcomes after percutaneous coronary intervention: a multicenter registry cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Jeong Tae","family":"Byoun","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital","place":["Iksan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyeon","family":"Joo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital","place":["Iksan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungho","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital","place":["Iksan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital","place":["Iksan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong Ho","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital","place":["Iksan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S0140-6736(23)00459-2","article-title":"Current concepts in coronary artery revascularisation","volume":"401","author":"Gaudino","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0133934","DOI":"10.1371\/journal.pone.0133934","article-title":"Combined usefulness of the platelet-to-lymphocyte ratio and the neutrophil-to-lymphocyte ratio in predicting the long-term adverse events in patients who have undergone percutaneous coronary intervention with a drug-eluting stent","volume":"10","author":"Cho","year":"2015","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e38692","DOI":"10.1097\/MD.0000000000038692","article-title":"Neutrophil to lymphocyte ratio as a prognostic marker for cardiovascular outcomes in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"103","author":"Ul Hussain","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.amjcard.2006.11.066","article-title":"Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial)","volume":"99","author":"Nikolsky","year":"2007","journal-title":"Am J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.ehj.2003.09.008","article-title":"Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions","volume":"24","author":"Reinecke","year":"2003","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1177\/2047487319870346","article-title":"Platelet-to-hemoglobin ratio as a novel predictor of long-term adverse outcomes in patients after percutaneous coronary intervention: a retrospective cohort study","volume":"27","author":"Zheng","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/s12872-021-02423-6","article-title":"Platelet-to-hemoglobin ratio as a valuable predictor of long-term all-cause mortality in coronary artery disease patients with congestive heart failure","volume":"21","author":"Bao","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e26833","DOI":"10.7759\/cureus.26833","article-title":"Platelet-to-hemoglobin ratio is an important predictor of in-hospital mortality in patients with ST-segment elevation myocardial infarction","volume":"14","author":"I\u015f\u0131k","year":"2022","journal-title":"Cureus"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.3390\/jcm14196780","article-title":"The platelet-to-hemoglobin ratio as a prognostic marker in patients with diabetes mellitus and acute coronary syndrome","volume":"14","author":"Kofos","year":"2025","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2147\/VHRM.S562298","article-title":"Platelet-to-hemoglobin ratio in predicting major adverse cardiovascular events after coronary artery bypass grafting","volume":"21","author":"Chen","year":"2025","journal-title":"Vasc Health Risk Manag"},{"key":"B11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2307\/2983064","article-title":"Spurious correlation and the fallacy of the ratio standard revisited","volume":"156","author":"Kronmal","year":"1993","journal-title":"J R Stat Soc Ser A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"B14","volume-title":"Guideline on Haemoglobin Cutoffs to Define Anaemia in Individuals and Populations","year":"2024"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/00033197211070908","article-title":"The prognostic utility of mean platelet volume in patients with acute coronary syndrome: a systematic review with meta-analyses","volume":"73","author":"Galimzhanov","year":"2022","journal-title":"Angiology"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1981126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:27Z","timestamp":1791519987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1981126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":18,"alternative-id":["10.3389\/fcvm.2026.1981126"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1981126","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1981126"}}